Presentaties 2016

09.05 – 10.45 Session 1 Diagnosis and screening

09:05 Epidemiology of GI tumors: state of the art
Dr. (Rob) R.H. Verhoeven, epidemiologist, IKNL

09:45 Surveillance and early detection of pancreas carcinoma
Prof.dr. (Marco) M.J. Bruno, gastroenterologist, Erasmus MC

10:05 Diagnosis and surveillance in HCC
Dr. (Karel) K.J. van Erpecum, gastroenterologist, UMCU

10:25 Screening for bowel cancer: what have we learned?
Prof.dr. (Evelien) E. Dekker, gastroenterologist, AMC

13.15 – 14.35 Session 3 Minimal invasive treatments

13:55 Minimal invasive surgery in gastric & oesophageal cancer
Dr. (Misha) M.D.P. Luyer, surgeon, Catharina Ziekenhuis

09.00 – 10.30 Session 6 Metastatic disease

09:50 New systemic options in metastic pancreatic cancer
Drs. (Judith) J. de Vos, medical oncologist, MUMC+

10:10 Clinical implications of molecular subgroups in metastatic CRC, and the role of the
PLCRC
Dr. (Miriam) M. Koopman, medical oncologist, UMCU

11.00 – 12.00 Session 7 Peritoneal carcinomatosis

11:30 Prevention of peritonitis carcinomatosis from high risk tumorsDr. (Pieter) P.J. Tanis, surgeon, AMC

12.00-12.30 Session 8 Debate 

12:00 This House believes that prognosis in Upper GI will be improved by better surgery
Dr. (Suzanne) S.S. Gisbertz, surgeon, AMC
14:30 LAPC: Evidence for FOLFIRINOX, nanoknife and surgical resections
Prof.dr. (Olivier) O.R.C. Busch, surgeon, AMC

14:30 LAPC: evidence for FOLFIRINOX, nanoknife and surgical resections
Dr. (Bas) B. Groot Koerkamp, surgeon, Erasmus MC

14:50 IORT in Locally Advanced and Recurrent Rectal cancer: is there any evidence?
Prof dr. (Hans) J.H.W. de Wilt, surgeon, Radboudumc

15:10 Surgery after chemoradiotherapy for locally advanced esophageal cancer. A reasonable and safe option?
Dr. (Jelle) J.P. Ruurda, surgeon, UMCU